VotedBy VotedBy ⌕
Election Day · Tue, Nov 3See how your members of Congress voted →

S. 1123 · 115th Congress

Office of National Drug Control Policy Reauthorization Act of 2017

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

1 cosponsor · 1 D

1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

Office of National Drug Control Policy Reauthorization Act of 2017

What it does: CRS summary · Introduced in Senate · May 15, 2017

Office of National Drug Control Policy Reauthorization Act of 2017

This bill reauthorizes the Office of National Drug Control Policy through FY2023. It amends the definition of "demand reduction" in a National Drug Control Program to include screenings, interventions, promoting availability of and access to health care services, and support for long-term recovery from substance abuse disorders. It defines "illicit drug use," "illegal drug use," and like terms to include the illegal use of prescription drugs.

The Director of the National Drug Control Policy (Director) shall be directly responsible for demand reduction activities, supply reduction activities, and for state, local, and tribal affairs.

The Director shall require each National Drug Control Program agency to submit to the Director on an annual basis an evaluation of progress by the agency regarding implementation of drug recovery programs. The Director shall also ensure that drug recovery research is effectively disseminated by the National Drug Control Program agencies to state and local governments and nongovernmental agencies involved in demand reduction.

The President shall submit to Congress a National Drug Control Strategy, which shall set forth a comprehensive plan for the year to reduce illicit drug use and the consequences of such use by promoting prevention, early intervention, treatment, and recovery support for individuals with substance abuse disorders.

The Director shall submit to Congress a report evaluating high intensity drug trafficking areas (HIDTAs) as part of the National Drug Control Strategy, assessing drug enforcement task forces in HIDTAs, and assessing law enforcement intelligence sharing in HIDTAs.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: Office of National Drug Control Policy Reauthorization Act of 2017

Latest action (May 15, 2017): Read twice and referred to the Committee on the Judiciary.

Policy area: Crime and Law Enforcement · Origin: Senate · Introduced: May 15, 2017

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.